The role of polyphenolic compounds in the diet as inhibitors of platelet function

Gary P Hubbard1, Siegfried Wolffram, Julie A Lovegrove

  • 1School of Food Biosciences, University of Reading, Whiteknights, Reading, Berks, RG6 6AL, UK. g.p.hubbard@reading.ac.uk

Insights

Dietary polyphenols, like quercetin, show potential in inhibiting platelet activation, a key factor in cardiovascular disease. However, current dietary interventions did not significantly alter platelet aggregation in vivo.

Area of Science:

  • Cardiovascular disease research
  • Dietary interventions and health

Background:

  • Platelets are crucial in cardiovascular disease development.
  • Dietary components like polyphenols are investigated for their anti-platelet effects.
  • Antioxidants, including polyphenols from fruits and vegetables, can inhibit platelet function.

Purpose of the Study:

  • To investigate the in vitro effects of hydroxycinnamates and quercetin on platelet activation and signaling.
  • To examine the in vivo effects of a polyphenol-rich diet on platelet aggregation.

Main Methods:

  • In vitro studies on platelet activation and cell signaling pathways.
  • In vivo study with 20 subjects on a low-polyphenol diet followed by polyphenol-rich meals for 5 days.
  • Measurement of platelet aggregation and plasma flavonols at baseline and after intervention.

Main Results:

  • Hydroxycinnamates inhibited platelet function in vitro, but not at achievable dietary levels.
  • Quercetin demonstrated significant inhibition of platelet aggregation, intracellular calcium mobilization, and tyrosine phosphorylation in vitro.
  • Plasma flavonoid levels increased significantly after dietary intervention (P = 0.001).
  • No significant changes in ex vivo platelet aggregation were observed after the 5-day intervention.

Conclusions:

  • Quercetin shows promise as an inhibitor of platelet activation in vitro.
  • Dietary polyphenol interventions require further investigation to demonstrate in vivo efficacy in reducing platelet aggregation.
  • Individual polyphenol effects on platelet function need further study to clarify their role in cardiovascular disease risk.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...